



**Sharon**<sup>®</sup>  
BIO-MEDICINE LTD.  
ISO 9001 - 2008 Certified Company

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED JUNE 30, 2014

(Rs. in Lacs)

SR. NO.	PARTICULARS	STANDALONE				
		Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
1	Net Sales / Income from Operations	34,675.87	31,568.54	32,254.18	131,376.83	105,949.65
	Total Income	<b>34,675.87</b>	<b>31,568.54</b>	<b>32,254.18</b>	<b>131,376.83</b>	<b>105,949.65</b>
2	<b>Total Expenditure</b>					
	a) (Increase)/Decrease in Stock in Trade	(3,035.88)	(1,645.70)	(3,665.12)	(6,221.38)	(6,402.08)
	b) Consumption of Materials	26,577.02	21,670.36	26,297.80	94,808.62	76,675.83
	c) Purchases of Trading Goods	5,458.02	6,409.11	5,602.99	22,687.57	19,934.11
	d) Employees Cost	654.29	607.32	508.99	2,307.62	1,851.29
	e) Depreciation	298.70	419.89	386.14	1,535.44	1,203.50
	f) Other Expenditure	593.55	605.76	268.87	2,088.53	1,879.50
	Total	<b>30,545.70</b>	<b>28,066.74</b>	<b>29,399.67</b>	<b>117,206.40</b>	<b>95,142.15</b>
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items ( 1 - 2 )	4,130.17	3,501.80	2,854.51	14,170.43	10,807.50
4	Other Income	112.83	15.26	12.78	167.71	88.65
5	Profit from Operations before Interest & Exceptional items ( 3 + 4 )	4,243.00	3,517.06	2,867.29	14,338.14	10,896.15
6	Interest	1,417.92	1,401.03	1,073.13	5,313.78	4,277.19
7	Profit after interest but before Exception items (5-6)	2,825.08	2,116.03	1,794.16	9,024.36	6,618.96
8	Exception Items	(145.31)	(141.99)	-	548.98	-
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)	2,679.77	1,974.04	1,794.16	8,475.38	6,618.96
10	Tax Expenses	644.52	190.11	345.00	1,513.66	1,333.06
11	Net Profit before ordinary activities ( 9 - 10 )	2,035.25	1,783.93	1,449.16	6,961.72	5,285.90
12	Extra Ordinary Items (Net of Tax)	-	-	-	-	-
13	Net Profit after Taxes ( 11 - 12 )	<b>2,035.25</b>	<b>1,783.93</b>	<b>1,449.16</b>	<b>6,961.72</b>	<b>5,285.90</b>
14	Paid up Equity Share Capital (Face value of Rs.2/- each)	2,111.38	2,111.38	1,055.69	2,111.38	1,055.69
15	Reserves excluding Revaluation Reserves	33,327.88	-	24,169.37	33,327.04	24,169.37
16	<b>Earning Per Shares</b>					
	i) EPS	1.93	1.69	13.73	6.59	50.07
	ii) Diluted EPS	1.36	1.19	10.65	4.65	38.85

Part-II

SR. NO.	PARTICULARS	Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
(A)	Aggregate of Public Shareholdings					
	No. of Shares	42,012,258	42,017,020	4,194,125	42,012,258	4,194,125
	Percentage of Shareholdings	39.80%	39.80%	39.73%	39.80%	39.73%
17	Promoters & promoter group Shareholding					
	a) Pledged / Encumbered					
	- Number of Shares	5,000,000	NIL	327,500	5,000,000	327,500
	- Percentage of Shares	7.94%	NIL	5.15%	7.94%	5.15%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	4.73%	NIL	3.10%	4.73%	3.10%
	(as a % of the total share capital of the Company)					
	b) Non-encumbered					
	- Number of Shares	63,556,742	62,551,980	6,035,275	63,556,742	6,035,275
	- Percentage of Shares	92.60%	100.00%	94.85%	92.60%	94.85%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	55.47%	60.20%	57.17%	55.47%	57.17%
	(as a % of the total share capital of the Company)					

9

Office Add. : Plot No: 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West) Mumbai - 400 053  
Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

*Caring for relationships*

CIN NO. L24110MH1989PLC052251



**Sharon**<sup>®</sup>

**BIO-MEDICINE LTD.**  
ISO 9001 - 2008 Certified Company

**AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED JUNE 30, 2014**

(Rs. in Lacs)

SR. NO.	PARTICULARS	CONSOLIDATED				
		Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
1	Net Sales / Income from Operations	34,951.87	31,848.54	32,526.12	132,479.28	107,351.53
	Total Income	<b>34,951.87</b>	<b>31,848.54</b>	<b>32,526.12</b>	<b>132,479.28</b>	<b>107,351.53</b>
2	<b>Total Expenditure</b>					
	a) (Increase)/Decrease in Stock in Trade	(3,035.88)	(1,645.70)	(3,665.12)	(6,221.38)	(6,402.08)
	b) Consumption of Materials	26,577.02	21,670.36	26,297.80	94,808.62	76,675.83
	c) Purchases of Trading Goods	5,713.02	6,665.11	5,821.99	23,708.35	20,842.05
	d) Employees Cost	656.84	609.67	516.04	2,336.17	1,861.29
	e) Depreciation	298.70	419.89	386.14	1,535.44	1,212.78
	f) Other Expenditure	595.53	607.54	271.17	2,096.51	2,270.99
	Total	<b>30,805.23</b>	<b>28,326.87</b>	<b>29,628.02</b>	<b>118,263.71</b>	<b>96,460.86</b>
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items ( 1 - 2 )	4,146.64	3,521.67	2,898.10	14,215.57	10,890.67
4	Other Income	115.33	17.76	12.78	193.34	119.00
5	Profit from Operations before Interest & Exceptional items ( 3 + 4 )	4,261.97	3,539.43	2,910.88	14,408.91	11,009.67
6	Interest	1,417.92	1,401.03	1,073.13	5,314.02	4,306.13
7	Profit after Interest but before Exception items (5-6)	2,844.05	2,138.40	1,837.75	9,094.89	6,703.54
8	Exception Items	(145.31)	(141.99)	-	548.98	-
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)	2,698.74	1,996.41	1,837.75	8,545.91	6,703.54
10	Tax Expenses	644.52	190.11	345.00	1,513.66	1,333.06
11	Net Profit before ordinary activities ( 9 - 10 )	2,054.22	1,806.30	1,492.75	7,032.25	5,370.48
12	Extra Ordinary Items (Net of Tax)					
13	Net Profit after Taxes ( 11 - 12 )	<b>2,054.22</b>	<b>1,806.30</b>	<b>1,492.75</b>	<b>7,032.25</b>	<b>5,370.48</b>
14	Paid up Equity Share Capital (Face value of Rs.2/- each)	2,111.38	2,111.38	1,055.69	2,111.38	1,055.69
15	Reserves excluding Revaluation Reserves	34,164.19	-	24,102.60	34,164.19	24,102.60
16	<b>Earning Per Shares</b>					
	i) EPS	1.95	1.71	14.14	6.66	50.87
	ii) Diluted EPS	1.37	1.21	10.97	4.70	39.47

**Part -II**

SR. NO.	PARTICULARS	Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
(A)	Aggregate of Public Shareholdings					
	No. of Shares	42,012,258	42,017,020	4,194,125	42,012,258	4,194,125
	Percentage of Shareholdings	39.80%	39.80%	39.73%	39.80%	39.73%
17	Promoters & promoter group Shareholding					
	<b>a) Pledged / Encumbered</b>					
	- Number of Shares	5,000,000	NIL	327,500	5,000,000	327,500
	- Percentage of Shares	7.94%	NIL	5.15%	7.94%	5.15%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	4.73%	NIL	3.10%	4.73%	3.10%
	(as a % of the total share capital of the Company)					
	<b>b) Non-encumbered</b>					
	- Number of Shares	63,556,742	62,551,980	6,035,275	63,556,742	6,035,275
	- Percentage of Shares	92.60%	100.00%	94.85%	92.60%	94.85%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	55.47%	60.20%	57.17%	55.47%	57.17%
	(as a % of the total share capital of the Company)					

9

Office Add. : Plot No: 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West) Mumbai - 400 053

Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

*Caring for relationships*

CIN NO. L24110MH1989PLC052251





**Sharon**<sup>®</sup>  
BIO-MEDICINE LTD.  
ISO 9001 - 2008 Certified Company

**NOTES :-**

Standalone and Consolidated Statement of Assets and Liabilities

(Rs. in Lacs)

	Particulars	STANDALONE		CONSOLIDATED	
		Year Ended on 30/06/2014	Year Ended on 30/06/2013	Year Ended on 30/06/2014	Year Ended on 30/06/2013
<b>A</b>	<b>EQUITY AND LIABILITIES</b>				
1	<i>Shareholders' funds</i>				
	(a.) Share Capital	2,111.38	1,055.69	2,111.38	1,120.24
	(b.) Reserves and Surplus	32,382.88	23,337.04	33,119.19	24,102.60
	(c.) Money received against share warrants	-	-	-	-
	<b>Sub-Total - ShareHolders Funds</b>	<b>34,394.26</b>	<b>24,392.73</b>	<b>35,230.57</b>	<b>25,222.84</b>
2	<i>Share application money pending allotment</i>	8,055.50	5,475.00	8,055.50	5,475.00
3	<i>Minority Interest</i>	-	-	-	-
4	<i>Non Current Liabilities</i>				
	(a.) Long term borrowings	29,141.93	28,086.75	29,141.93	28,086.75
	(b.) Deferred Tax Liabilities (Net)	1,045.00	832.33	1,045.00	832.33
	(c.) Other Long Term Liabilities	-	-	-	-
	(d.) Long Term Provisions	52.94	52.94	52.94	52.94
	<b>Sub-Total - Non current liabilities</b>	<b>30,239.87</b>	<b>28,972.02</b>	<b>30,239.87</b>	<b>28,972.02</b>
5	<i>Current Liabilities</i>				
	(a.) Short term borrowings	43,396.43	36,302.06	43,396.44	36,302.06
	(b.) Trade Payables	6,118.15	5,985.54	6,137.19	6,006.00
	(c.) Other Current Liabilities	197.29	155.79	197.29	155.79
	(d.) Short term provision	1,745.64	1,385.27	1,745.64	1,385.27
	<b>Sub-Total - Current liabilities</b>	<b>51,457.51</b>	<b>43,828.66</b>	<b>51,476.56</b>	<b>43,849.12</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>116,091.64</b>	<b>97,193.41</b>	<b>116,947.00</b>	<b>98,043.98</b>
<b>B</b>	<b>ASSETS</b>				
1	<i>Non Current Assets</i>				
	(a.) Fixed Assets	33,994.67	31,436.20	33,994.67	31,436.20
	(b.) Goodwill on consolidation	-	-	-	-
	(c.) Non Current Investments	123.24	398.24	58.69	398.23
	(d.) Deferred Tax Assets (Net)	-	-	-	-
	(e.) Long term Loans and Advances	-	-	-	-
	(f.) Other non-current assets	-	-	-	-
	<b>Sub-Total - Non Current Assets</b>	<b>34,117.91</b>	<b>31,834.44</b>	<b>34,053.36</b>	<b>31,834.43</b>
2	<i>Current Assets</i>				
	(a.) Current Investments	-	-	-	-
	(b.) Inventories	32,245.02	26,023.64	32,245.02	26,023.64
	(c.) Trade receivables	41,431.08	35,509.89	42,261.04	36,351.91
	(d.) Cash and Cash equivalents	1,227.33	627.34	1,234.30	631.82
	(e.) Short term Loans and Advances	7,070.30	3,198.11	7,153.28	3,210.57
	(f.) Other Current Assets	-	-	-	-
	<b>Sub-Total - Current Assets</b>	<b>81,973.73</b>	<b>65,358.98</b>	<b>82,893.64</b>	<b>66,217.94</b>
	<b>TOTAL - ASSETS</b>	<b>116,091.64</b>	<b>97,193.42</b>	<b>116,947.00</b>	<b>98,052.37</b>

1) The above results for the quarter ended June 30, 2014 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on August 28, 2014.

2) The "Limited Review" required under clause 41 of Listing agreement has been done by statutory auditors of the Company.

3) The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the period(s) on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds.

4) Shares has been split in the ratio of 1:5, subdividing the face value of Shares to Rs. 2/- from Rs. 10/- during the Quarter ended March, 2014.

5) Company has issued Bonus Shares in the ratio of 1:1 during the quarter ended March, 2014.

6) Previous years figures have been regrouped and recast wherever necessary.

7) The company is dealing in single segment. Therefore, segment reporting is not applicable.

8) Information on investor complaints for the quarter ended June 30, 2014 ( In Nos.)

Opening Balance of Complaints	Received during the Quarter	Disposed off during the Quarter	Closing Balance
NIL			NIL

For Sharon Bio-Medicine Ltd.

Sayita Gowda  
Managing Director.

Place : Mumbai.  
Date : 29.08.2014

Office Add. : Plot No: 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West) Mumbai - 400 053  
Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

*Caring for relationships* CIN NO. L24110MH1989PLC052251